Potency of Experimental Drug Confirmed Against Chemo-resistant Ovarian Cancer Stem Cells
pennyomega Newsletter
(Mailing list information, including instructions, is located at the end of this message.)
Novogen Limited (NVGN)
NVGN and CanTx Inc., its joint venture with Yale University, reported the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.
NVGN and CanTx believe that Intra-Peritoneal Trx-1 could be utilized as a first-line therapy for ovarian cancer.
NVGN and CanTx plan to file an Investigational New Drug application (IND) with the FDA in early 2015 and to start a Phase 1 study by mid-2015.
NVGN , an Australian drug-development company, has two main drug technology platforms: super-benzopyrans and anti-tropomyosins (ATMs).. SBP compounds have been created to have a uniform cytotoxic effect against both cancer stem cell and are being developed in the first instance for the treatment of ovarian cancer, glioblastoma and prostate cancer. ATM compounds target the cancer cell cytoskeleton and are being developed for the treatment of melanoma and neuroblastoma.
More about Novogen Limited (NVGN) at www.pennyomega.com/disclaimer
pennyomega.com
No related posts.